Neurological Peptide Drugs
Total Trials
2
As Lead Sponsor
As Collaborator
0
Total Enrollment
109
NCT05827653
MAD Study of NX210c
Phase: Phase 1
Role: Lead Sponsor
Start: Dec 5, 2022
Completion: Oct 2, 2023
NCT06365216
ALS Phase II Study of NX210c
Phase: Phase 2
Start: Oct 25, 2024
Completion: Feb 1, 2026
Loading map...